CN115558618A - Staphylococcus cohnii and application thereof - Google Patents
Staphylococcus cohnii and application thereof Download PDFInfo
- Publication number
- CN115558618A CN115558618A CN202211194563.XA CN202211194563A CN115558618A CN 115558618 A CN115558618 A CN 115558618A CN 202211194563 A CN202211194563 A CN 202211194563A CN 115558618 A CN115558618 A CN 115558618A
- Authority
- CN
- China
- Prior art keywords
- expression
- gene
- regulation
- staphylococcus cohnii
- extracellular matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001147698 Staphylococcus cohnii Species 0.000 title claims abstract description 35
- 238000004321 preservation Methods 0.000 claims abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 36
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 27
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 27
- 210000002744 extracellular matrix Anatomy 0.000 claims description 27
- 210000003491 skin Anatomy 0.000 claims description 21
- 230000002757 inflammatory effect Effects 0.000 claims description 16
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 12
- 230000003712 anti-aging effect Effects 0.000 claims description 10
- 230000003827 upregulation Effects 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 230000002222 downregulating effect Effects 0.000 claims description 9
- 101000704221 Homo sapiens Serine palmitoyltransferase small subunit A Proteins 0.000 claims description 8
- 108010082399 Autophagy-Related Proteins Proteins 0.000 claims description 6
- 108010052500 Calgranulin A Proteins 0.000 claims description 6
- 108010076667 Caspases Proteins 0.000 claims description 6
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 6
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 claims description 6
- 102100031872 Serine palmitoyltransferase small subunit A Human genes 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 102100032442 Protein S100-A8 Human genes 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 210000004927 skin cell Anatomy 0.000 claims description 5
- 102000011727 Caspases Human genes 0.000 claims description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 210000001808 exosome Anatomy 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 102100032446 Protein S100-A7 Human genes 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 101100498892 Aedes aegypti DEFB gene Proteins 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 239000006228 supernatant Substances 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- 101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 description 4
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 102100026886 Beta-defensin 104 Human genes 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000002247 constant time method Methods 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 108010024814 Serine C-palmitoyltransferase Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 240000001417 Vigna umbellata Species 0.000 description 2
- 235000011453 Vigna umbellata Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 1
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 101710125300 Beta-defensin 4 Proteins 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101000945357 Homo sapiens Collagen alpha-1(I) chain Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/44—Staphylococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of microorganisms, and particularly provides a staphylococcus cohnii strain and application thereof, wherein the strain has a code of ProfMIC-216 and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M20221129. The strain has effects of resisting aging and improving cell antibacterial ability, and can be used for preparing food, medicine, cosmetic, etc.
Description
Technical Field
The invention mainly relates to the field of microorganisms and application thereof, and particularly relates to staphylococcus cohnii and application thereof.
Background
The skin is the first line of defense of the body, and plays an important role in resisting various external aggressions, maintaining the homeostasis and guaranteeing the physiological function of the body. Skin aging is divided into two types: one is due to aging, in vivo cell metabolism decline, leading to skin natural aging; the other is skin aging due to external environmental factors. In the research of an aging mechanism, the autophagy of cells can delay the functional degradation of organs, and can help the cells to restore the metabolic homeostasis by removing damaged proteins and lipids in UV irradiated cells and repairing DNA, thereby providing a protective effect for photoaging damaged skin. In addition, reduction of apoptosis, reduction of cellular inflammation, increase in extracellular matrix synthesis and decrease in degradation, improvement of cell antioxidant capacity, etc. have all been shown to slow down skin cell aging.
In addition, the skin can protect the host skin actively or passively through a variety of mechanisms, one of which is the secretion of antimicrobial peptides inherent to the epidermis. The skin symbiotic bacteria can regulate the inflammatory reaction of the damaged skin and participate in local immune defense by regulating the generation of the antibacterial peptide. The skin normal symbiotic bacteria can also inhibit the propagation of pathogenic microorganisms by directly secreting or inducing an organism to generate antibacterial peptide. The antibacterial peptide is mainly secreted by epithelial cells on the surface layer of the mucous membrane, and is expressed in cells of eyes, skin, oral mucosa, urogenital system and respiratory system. Antimicrobial peptides have a direct effect on most bacteria, certain fungi and viruses. Its common mode of action is through its own positive charge and bacterial cell membrane on the negative charge of the component (such as lipopolysaccharide) interact, thus increase the permeability of bacterial cell membrane, the lysis bacterium, cause the death of bacterium. The skin's innate immune system in combination with the skin's microflora is the body's barrier against pathogenic and opportunistic pathogens. Skin has self-renewal ability, and skin microorganisms decompose phospholipids, sterols and keratin, which also can make skin cells absorb and promote cell growth, delay aging and reduce wrinkle generation.
Therefore, the anti-aging substance can play a role in inhibiting different skin aging ways and improving the state of skin cells to resist the aging process to the maximum extent, and therefore whether a multi-layer and multi-dimensional anti-aging substance can be searched is a current research hotspot.
Disclosure of Invention
In order to realize the technical purpose, the invention provides Staphylococcus cohnii (Staphylococcus cohnii) which is named as ProfMIC-216 and has the preservation number of CCTCC NO: M20221129. After research, the strain is found to have the functions of promoting cell proliferation, repairing skin barrier and resisting aging, and can be used for preparing medicines, cosmetics and the like.
The invention provides Staphylococcus cohni with the preservation number of CCTCC NO: M20221129, which is preserved in the China center for type culture collection.
The Staphylococcus cohnii is derived from isolated skin of children. The strain is gram-positive and spherical under a microscope; growing on a BHI flat plate to form a round colony with a smooth and opaque surface, white color and regular edges; the strain is Staphylococcus cohnii (Staphylococcus cohnii) after the strain is subjected to uniform turbid growth in a BHI liquid culture medium, the white precipitation of the strain is caused after long-time placement, the optimal growth temperature is 37 ℃, and the strain is obtained by carrying out homology comparison (BLASTN) on a sequencing result and a standard sequence published in GenBank.
After obtaining the staphylococcus cohnii, the inventor further claims the application of the staphylococcus cohnii in preparing products for improving skin cell conditions.
Wherein the product is food, medicine or cosmetic, and the effective component of the product in any form comprises staphylococcus cohnii or its derivative with the preservation number of CCTCC NO: M20221129;
wherein the staphylococcus cohnii is live and/or inactivated; the staphylococcus cohnii derivative comprises a culture, an exosome, a lysate and/or an extract thereof.
The improvement in skin condition includes at least one of anti-aging, and increasing the antibacterial ability of cells.
In the specific technical scheme of the invention, the anti-aging is the up-regulation of the expression of extracellular matrix related genes, and/or the up-regulation of the expression of cell autophagy related genes LC3B, and/or the up-regulation of the expression of cell anti-oxidation related genes NRF2 and/or SIRT-3, and/or the up-regulation of the expression of immunoregulatory factor related genes MOR;
wherein the extracellular matrix-associated gene includes at least one of TIMP1, SPTSSA and COL1A 1.
Besides, the anti-aging can also be the expression of genes related to the degradation of extracellular matrix by down regulation; and/or down-regulating expression of apoptosis-related genes; and/or down-regulating the expression of a gene associated with a cellular inflammatory factor;
wherein the extracellular matrix-associated gene of interest comprises at least one of the MMP families;
the apoptosis-related gene comprises at least one of Caspase family;
the genes related to the cell inflammatory factors comprise TNF-alpha and/or IL-6.
In some technical schemes, the method for improving the cell antibacterial ability is to up-regulate the expression of antibacterial peptide related genes; the antibacterial peptide related gene comprises at least one of S100A7, S100A8 and DEFB 4.
The inventor further provides a product for improving skin conditions, wherein the product is food or medicine or cosmetics, and the effective components of the product in any form comprise staphylococcus cohnii with the preservation number of CCTCC NO: M20221129 or derivatives thereof;
wherein the staphylococcus cohnii is live bacteria and/or inactivated bacteria; the staphylococcus cohnii derivative comprises a culture, an exosome, a lysate and/or an extract thereof.
In conclusion, the invention provides staphylococcus cohnii and application thereof, the strain is named as Prof MIC-216, has the functions of resisting aging and improving the cell antibacterial ability, and can be used for preparing related foods, medicines, cosmetics and the like.
Preservation information
Preservation time: 7 month, 18 days 2022;
the name of the depository: china center for type culture Collection;
the preservation number is as follows: CCTCC NO, M20221129;
the address of the depository: china, wuhan university;
and (3) classification and naming: staphylococcus cohnii ProfMI C-216 (Staphylococcus cohnii ProfMI C-216).
Detailed Description
The present invention will be described in further detail with reference to the following examples, but it should not be construed that the scope of the above subject matter is limited to the following examples. The present invention is not limited to the above-described embodiments, and the following examples are made by conventional techniques, and all materials used are commercially available.
Staphylococcus cohnii (Staphylococcus cohnii) in the following examples, which originated from the skin of children ex vivo and was identified as Staphylococcus cohnii (Staphylococcus aureus) by 16S rDNA. The strain is gram-positive and spherical under a microscope; growing on a BHI flat plate to form a round colony with a smooth and opaque surface, white color and regular edges; the strain grows uniformly and turbulently in BHI liquid culture medium, the strain is white precipitate after long-time placement, the optimal growth temperature is 37 ℃, and the strain is preserved in China Center for Type Culture Collection (CCTCC) NO: M20221129.
Examples the following examples illustrate the ProfMIC-216 of Staphylococcus cohnii in a particular application or product in the form of live or dead or tyndallized, or in the form of lysate and/or extract, or in the form of bacterial product or in the form of supernatant or derivative, preferably selected from: metabolites, metabolic biological products, exosomes, prebiotics, cell walls and components thereof, exopolysaccharides, and compounds containing immunogenic components, preferably selected from: supernatant and inactivated bacteria.
EXAMPLE 1 isolation of ProfMIC-216
The inventor samples on the in-vitro skin of a five-year-old child, properly processes the sample, uniformly vibrates the sample in normal saline, takes the supernatant to mark on a BHI solid plate, cultures the supernatant at the constant temperature of 37 ℃ for 48 hours, and picks a white colony for repeated inoculation and screening until a uniform single colony is obtained, wherein the colony is named as ProfMIC-216.
Gram staining microscopy: the strain ProfMIC-216 is gram-positive and is spherical under a microscope; growing on a BHI flat plate to form white or light gray round microcolonies with smooth, mellow and opaque surfaces and regular edges; the bacteria grow uniformly and turbulently in BHI liquid culture medium, and the bacteria are white precipitate after being placed for a long time.
Example 2 nucleic acid identification of ProfMIC-216
1. 16S rDNA gene sequence analysis:
picking single colony to be placed in BHI liquid culture medium, culturing overnight at 37 ℃, then rotating and centrifuging for 1min at 12000 ℃ to collect thalli, and operating according to the steps of the DNA extraction kit. The primers adopt bacterial universal primers 27F and 1492R, a PCR amplification system is a 50 mu L system, and the pre-denaturation is carried out for 5min at 95 ℃;94 ℃ 15s,57 ℃ 15s,72 ℃ 40s,35 cycles; extension at 72 ℃ for 10min.
2. Results
The homology comparison of the PCR product sequencing results with the published standard sequences in GenBank (BLAST N) gave that the ProfMIC-216 strain was Staphylococcus cohnii.
Example 3ProfMIC-216 Regulation of photoaging HaCaT extracellular matrix/Oxidation/autophagy/inflammatory factor-related Gene expression assay
1. Preparation of ProfMIC-216 supernatant and inactivated thallus:
selecting Staphylococcus cohnii ProfMIC-216 single colony in BHI liquid culture medium, static culturing at 37 deg.C in incubator for 16-18h, detecting with microplate reader, diluting with PBS to adjust OD 600 And (3) inactivating at 121 ℃ for 30min under high pressure, centrifuging at 12000 rpm for 2min, and filtering with 0.22 μm filter membrane to obtain supernatant. Resuspending the pellet with PBS, diluting and adjusting OD 600 And =0.2, which is an inactivated cell.
2. HaCaT cell preparation and ultraviolet ray damage
HaCaT cells were digested and then dispensed at 0.5 ml/well (2X 10 contents) 5 Cells) were inoculated into 24-well plates and cultured overnight at 37 ℃ in a 5% carbon dioxide incubator. Total dose of 2J/cm was applied to cells in the wells 2 Ultraviolet UVB radiation damage.
3. ProfMIC-216 addition
The volume percentage of the supernatant to be added to the stimulated HaCaT cells is 5% and the volume percentage of the inactivated bacteria to be added to the stimulated HaCaT cells is 10% (the control group replaces the supernatant/the inactivated bacteria with PBS with equal volume respectively). Each group 3 was incubated overnight at 37 ℃.
4. qPCR method for detecting relative expression multiple of extracellular matrix/antioxidant/autophagy/inflammatory factor related genes
Removing a culture medium from the cells, adding a lysis solution, extracting total RNA of the cells, detecting the concentration and purity of the RNA, performing reverse transcription to obtain cDNA, and detecting the expression of extracellular matrix related genes COL1A1, TIMP1 and SPTSSA, antioxidant related gene NRF2, autophagy related gene LC3B and inflammatory factor related gene TNF-alpha by using GAPDH as an internal reference gene and adopting real-time qPCR. Relative expression multiple F =1 of control group gene, using 2 -ΔΔCT Calculating the F value of each sample;
the formula: f =2 -ΔΔCT Wherein:
△CT experiment of ＝CT Experiment of -CT Internal reference (experiment) ；
△CT Control ＝CT Control of -CT Internal reference (contrast) ；
△△CT＝△CT Experiment of -△CT Control 。
The supernatant liquid can regulate the extracellular matrix related gene TIMP1 and the autophagy related gene LC3B; down-regulating the inflammatory factor related gene TNF-alpha. The results are given in the following table:
the inactivated thallus can up-regulate extracellular matrix related genes TIMP1, COL1A1 and SPTSSA, antioxidant related gene NRF2 and autophagy related gene LC3B. The results are shown in the following table:
the results show that the addition of ProfMIC-216 has the anti-aging effects of promoting the synthesis of HaCaT extracellular matrix, resisting oxidation and autophagy and reducing inflammatory factors.
Example 4ProfMIC-216 Regulation of oxidative damage HFF extracellular matrix/apoptosis/antioxidant/immunomodulatory factor/inflammatory factor-related Gene expression assay
1. Preparing ProfMIC-216 supernatant and inactivated thallus:
the preparation method refers to example 3.
2. HFF cell preparation and H 2 O 2 Inducing oxidative damage
The HFF cells cultured with DMEM were digested at 0.5 ml/well (2X 10 contained therein) 5 Cells) were seeded into 24-well plates and cultured overnight at 37 ℃ in a 5% carbon dioxide incubator. H was added to each well to a final concentration of 200. Mu.M 2 O 2 Stimulating, and standing at 37 ℃ for 1h.
3. ProfMIC-216 addition
The volume percentage of 5% supernatant and 10% inactivated bacteria were added to the stimulated HFF cells (equal volume of PBS was used for the control group instead of supernatant/inactivated bacteria, respectively). Each group 3 was incubated overnight at 37 ℃.
4. qPCR method for detecting relative expression multiple of extracellular matrix/apoptosis/antioxidation/immunoregulation factor/inflammatory factor related gene
Removing the culture medium of the cells, adding lysis solution, extracting total RNA of the cells, detecting the concentration and purity of the RNA, performing reverse transcription to obtain cDNA, detecting an extracellular matrix related gene SPTSSA, an antioxidant related gene SIRT-3 and an immunoregulation related gene MOR by using GAPDH as an internal reference gene and adopting real-time qPCR; and degrading the expression of MMP family of extracellular matrix related genes, caspase family of apoptosis related genes and IL-6 of inflammatory factor related genes. Relative expression multiple F =1 of control group gene, using 2 -ΔΔCT The F value of each sample was calculated.
The supernatant fluid up-regulates extracellular matrix related gene SPTSSA, immunoregulation related gene MOR; down-regulating and degrading MMP family of extracellular matrix related genes and Caspase family of apoptosis related genes, and the results are shown in the following table:
the inactivated thallus up-regulates an anti-oxidation related gene SIRT-3; down-regulating and degrading extracellular matrix related gene MMP family, apoptosis related gene Caspase family and inflammatory factor related gene IL-6, and obtaining the results shown in the following table:
the results show that the addition of ProfMIC-216 has the anti-aging effects of promoting HFF extracellular matrix synthesis, reducing apoptosis, increasing antioxidation, reducing extracellular matrix degradation, reducing inflammatory factors and regulating immunity.
Example 5ProfMIC-216 Up-Regulation of HaCaT antimicrobial peptide-related Gene expression experiments
1. Preparing a ProfMIC-216 supernatant and inactivated bacteria:
the preparation method refers to example 3.
2. HaCaT cell preparation
HaCaT cells were digested and then dispensed at 0.5 ml/well (2X 10 contents) 5 Cells) were inoculated into 24-well plates and cultured overnight at 37 ℃ in a 5% carbon dioxide incubator.
3. ProfMIC-216 addition and LPS stimulation
The supernatant and the inactivated thallus are respectively added into HaCaT cells which are cultured overnight according to the proportion of 5 percent by volume of the supernatant and 10 percent by volume of the inactivated thallus (the control group respectively replaces the supernatant and the inactivated thallus by PBS with equal volume), 0.5ml of LPS solution with the concentration of 0.2 mu g/ml is added after 2 hours, cell inflammation is induced, and the cells are cultured for 20 hours in a 5 percent carbon dioxide incubator at 37 ℃.
4. qPCR method for detecting relative expression multiple of antibacterial peptide related gene
Removing the culture medium of the cells, adding a lysis solution, extracting total RNA of the cells, detecting the concentration and purity of the RNA, performing reverse transcription to obtain cDNA, and detecting the expression of S100A7, S100A8 and DEFB4 genes by using a real-time qPCR (quantitative polymerase chain reaction) by using GAPDH as an internal reference gene. Control with an equal volume of PBS-treated group (gene relative expression fold F = 1) using 2 -ΔΔCT The F value of each sample was calculated.
The supernatant liquid is used for regulating antibacterial peptide genes S100A7, S100A8 and DEFB4, and the results are shown in the following table:
ProfMIC-216 supernatant up-regulated expression of antibacterial peptide related gene
The results of the inactivated thallus up-regulating antibacterial peptide genes S100A7, S100A8 and DEFB4 are shown in the following table:
ProfMIC-216 inactivated thallus for up-regulating expression of antibacterial peptide related gene
The result shows that ProfMIC-216 has the function of promoting the expression of the antibacterial peptide gene.
In conclusion, the staphylococcus cohnii ProfMIC-216 has the effects of up-regulating expression of tissue metalloproteinase inhibitor 1 gene TIMP1, serine palmitoyltransferase gene SPTSSA, collagen type I alpha 1 chain gene COL1A1, antioxidant-related nuclear factor E2-related factor 2 gene NRF2 and cell autophagy-related microtubule-related protein 1 light chain 3 beta gene LC3B, which are related to HaCaT extracellular matrix, and relative expression multiple of the genes is 1.12-1.47; has the function of down regulating the tumor necrosis factor alpha gene TNF-alpha related to the cell inflammatory factor, and the relative expression multiple of the gene is 0.57-0.68.
In vitro cell experiments show that the staphylococcus cohnii ProfMIC-216 has serine palmitoyltransferase gene SPTSSA related to up-regulated HFF extracellular matrix, antioxidant-related Sirtuins protein family gene SIRT-3 and immunoregulatory factor-related beta-endorphin receptor gene MOR, and the relative expression multiple of the gene is 1.13-1.46 times; has the function of down-regulating matrix metalloproteinase family gene MMP related to degradation of extracellular matrix, cysteine proteinase family gene Caspase related to apoptosis and interleukin 6 gene IL-6 related to cell inflammatory factor, and the relative expression multiple of the genes is 0.25-0.84.
In vitro cell experiments show that the ProfMIC-216 has the function of up-regulating the expression of related genes of the antimicrobial peptide, namely the psoriatin gene S100A7, the calgranulin A gene S100A8 and the beta defensin 4 gene DEFB4, and the relative expression multiple of the genes is 1.48-8.61.
The bacterial strain has the functions of resisting aging and improving the antibacterial capacity of cells, and can be used for preparing related foods, medicines, cosmetics and the like.
EXAMPLE 6 example preparation of supernatant infusion of Staphylococcus cohnii ProfMIC-216
The formulation of the ProfMIC-216 supernatant granule is shown in the following table:
| raw materials | Mass ratio (%) |
| ProfMIC-216 baking powder | 40.0 |
| Red bean and coix seed powder | 35.0 |
| Cocoa powder | 24.6 |
| Silicon dioxide | 0.4 |
The preparation process comprises the following steps: taking the supernatant of ProfMIC-216 prepared in the embodiment 3, spray-drying to prepare ProfMIC-216 fermentation powder, adding red bean and coix seed powder, cocoa powder and silicon dioxide, and stirring and dispersing uniformly to obtain ProfMIC-216 medicinal granules; the obtained instant granules of ProfMIC-216 are convenient to carry, have natural taste after being soaked in water, have good palatability, and can be used as oral beverage for skin care.
Example 7 preparation of emulsion of Staphylococcus cohnii ProfMIC-216 inactivated thallus
The formula of the staphylococcus aureus ProfMIC-216 inactivated thallus emulsion is shown in the following table:
the preparation process comprises the following steps: mixing cyclopentasiloxane, vaseline, tween-80, vitamin E acetate, and glycerol, and heating to 75 deg.C to obtain phase A; then adding xanthan gum, carbopol Ultrez 10, 1,3-butanediol and deionized water into the ProfMIC-216 inactivated bacterial liquid prepared in the embodiment 3, mixing, dispersing uniformly, and heating to 75 ℃ to be used as a phase B; slowly adding the preheated phase A into the preheated phase B, homogenizing completely, adding triethanolamine to adjust pH to 6-7, stirring, and cooling to 35 deg.C. The obtained ProfMIC-216 inactivated bacteria emulsion is lubricated and comfortable.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that it is obvious to those skilled in the art that various modifications and improvements can be made without departing from the principle of the present invention, and these modifications and improvements should also be considered as the protection scope of the present invention.
Claims (9)
1. A strain of Staphylococcus cohnii (Staphylococcus cohnii) is characterized in that the preservation number is CCTCC NO: M20221129.
2. Use of staphylococcus kojie according to claim 1 for the manufacture of a product for improving skin cell condition.
3. Use according to claim 2, characterized in that: the improvement in skin condition includes anti-aging and/or increasing the antibacterial ability of cells.
4. The use according to claim 3, wherein the anti-aging is up-regulation of the expression of extracellular matrix-related genes, and/or up-regulation of the expression of the autophagy-related genes LC3B, and/or up-regulation of the expression of cellular antioxidant-related genes NRF2 and/or SIRT-3, and/or up-regulation of the expression of the immunomodulatory factor-related gene MOR;
wherein the extracellular matrix-associated gene includes at least one of TIMP1, SPTSSA and COL1A 1.
5. The use according to claim 3, wherein the anti-aging is down-regulation of expression of extracellular matrix-associated genes; and/or down-regulating expression of apoptosis-related genes; and/or down-regulating the expression of a gene associated with a cellular inflammatory factor;
wherein the extracellular matrix-associated gene of interest comprises at least one of the MMP families;
the apoptosis-related gene comprises at least one of Caspase family;
the genes related to the cell inflammatory factors comprise TNF-alpha and/or IL-6.
6. The use of claim 3, wherein the improvement of the antibacterial ability of the cell is the up-regulation of the expression of an antibacterial peptide-related gene; the antibacterial peptide related gene comprises at least one of S100A7, S100A8 and DEFB 4.
7. Use according to any one of claims 1 to 6, wherein the product is a food or a pharmaceutical or a cosmetic product.
8. A product for improving skin conditions is characterized in that the effective component of the product comprises staphylococcus cohnii or a derivative thereof with the preservation number of CCTCC NO: M20221230.
9. The product of claim 8, wherein the staphylococcus cohnii is live and/or inactivated; the staphylococcus cohnii derivative comprises a culture, an exosome, a lysate and/or an extract thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211194563.XA CN115558618A (en) | 2022-09-28 | 2022-09-28 | Staphylococcus cohnii and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211194563.XA CN115558618A (en) | 2022-09-28 | 2022-09-28 | Staphylococcus cohnii and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115558618A true CN115558618A (en) | 2023-01-03 |
Family
ID=84742057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211194563.XA Pending CN115558618A (en) | 2022-09-28 | 2022-09-28 | Staphylococcus cohnii and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115558618A (en) |
-
2022
- 2022-09-28 CN CN202211194563.XA patent/CN115558618A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102085787B1 (en) | Nanovesicles derived from Bacillus bacteria and Use thereof | |
| CN114081901B (en) | Probiotic composition, preparation method and application thereof | |
| CN114806977B (en) | Lactobacillus salivarius and application thereof in preparation of anti-dermatitis products | |
| CN115094011A (en) | Lactobacillus gasseri and application thereof | |
| CN114645001A (en) | Lactobacillus paracasei and application thereof in preparation of product for regulating skin microecological system | |
| CN115678814A (en) | Lactobacillus salivarius and application thereof | |
| CN115584333A (en) | Lactobacillus reuteri and application thereof | |
| CN115261273A (en) | Lactobacillus jensenii and application thereof | |
| CN115558618A (en) | Staphylococcus cohnii and application thereof | |
| CN115369047A (en) | Kluyveromyces marxianus strain and application thereof | |
| CN115491334A (en) | Lactobacillus rhamnosus and application thereof | |
| CN115505550A (en) | Lactobacillus paracasei and application thereof | |
| CN116555070A (en) | Bifidobacterium bifidum and application thereof | |
| CN114891699A (en) | Lactobacillus salivarius for regulating flora balance | |
| CN114574408A (en) | Probiotic SEUNEU-107 and application thereof | |
| CN115678807B (en) | Bifidobacterium longum and application thereof | |
| CN115505544A (en) | Monascus ruber strain for improving skin condition and application thereof | |
| CN115820485A (en) | Lactobacillus helveticus strain and application thereof | |
| CN116286415B (en) | Brevibacterium citricum strain and application thereof | |
| CN115820476B (en) | Lactobacillus delbrueckii and application thereof | |
| CN115786208A (en) | Lactobacillus brevis and application thereof | |
| CN114561331B (en) | Lactobacillus paracasei and application thereof | |
| CN115651875A (en) | Staphylococcus epidermidis and application thereof | |
| CN116355770B (en) | Debaryomyces hansenii and application thereof | |
| CN115851466A (en) | Pichia jateorhii and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |